Edgewise Therapeutics Inc., a leading biopharmaceutical company focused on muscle diseases, announced new compensation terms as part of their 2024 Inducement Equity Incentive Plan. On July 31, 2025, the company granted inducement stock options to purchase 84,250 shares and inducement restricted stock units (RSUs) covering 5,000 shares to three new non-executive employees. The stock options have an exercise price of $14.26 per share, the closing price on the grant date. They will vest with 25% of the shares on the first anniversary of the employees' start date, and 1/48th of the shares monthly thereafter. The RSU awards will vest in equal annual installments over four years, starting on July 31, 2025, contingent on the employees' continued service. These grants are aligned with Nasdaq Listing Rule 5635(c)(4).
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。